Oncothyreon price target lowered to $4 from $11 at Cantor Cantor reduced its price target on Oncothyreon as the firm believes that the company's Stimuvax drug is no longer a commercial candidate. However, the firm believes that Oncothyreon's cancer treatment PX-866, along with its cash, could be worth about $3.90 per share. The firm maintains a Buy rating on the stock.
News For ONTY From The Last 14 Days
Check below for free stories on ONTY the last two weeks.